Study seminar on molecular imaging drug screening technology and low deuterium water research progresses smoothly in Changshu
On October 31, 2016, the “Molecular Imaging Drug Screening Technology and Low Deuterium Water Research Progress Seminar” hosted by Changshu New Material Industrial Park and organized by Jiangsu Huayi Technology Co., Ltd. was held in Changshu. More than 30 people in charge of universities, research institutes, experts in the field of biomedicine, hospitals and pharmaceutical companies across the country gathered together to discuss the latest cutting-edge developments in molecular imaging and low deuterium water research.
At the seminar, Zhou Lingqun, vice mayor of Changshu City, introduced the development of Changshu in the biomedical field in recent years. Jin Zhiming, general manager of Jiangsu Huayi Technology, delivered a welcome address. Pu Mingming, academician of the Institute of Neurosciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Professor Zhong Chunjue from Zhongshan Hospital Affiliated to Fudan University, Professor Guan Yihui from Huashan Hospital, and Professor Wang Feng from Nanjing First Hospital delivered wonderful reports on the progress of nervous system diseases, brain disease imaging research and other contents. The scientific researchers of Jiangsu Huayi Technology Co., Ltd. made reports and discussions on the role of molecular imaging in drug screening and the biological effects of low deuterium water.
In 2014, the Molecular Imaging Research Institute of Jiangsu Huayi Technology Co., Ltd., with a total investment of more than 60 million yuan, was officially put into use in Changshu New Material Industrial Park. In the past two years, the research institute has continuously improved the platform’s R&D capabilities, using molecular imaging technology for the development of the company’s new diagnostic contrast agents, and at the same time opening the molecular imaging platform to serve scientific research institutes and pharmaceutical companies for the development of new drugs and exploration of disease mechanisms. Through imaging means, some problems that cannot be solved by traditional methods are solved.
